Mometasone Furoate Inhibits the Progression of Head and Neck Squamous Cell Carcinoma via Regulating Protein Tyrosine Phosphatase Non-Receptor Type 11

Mometasone furoate (MF) is a kind of glucocorticoid with extensive pharmacological actions, including inhibiting tumor progression; however, the role MF in head and neck squamous cell carcinoma (HNSCC) still unclear. This study aimed to evaluate inhibitory effect against HNSCC investigate its underlying mechanisms. Cell viability, colony formation, cycle apoptosis were analyzed explore on cells. A xenograft model was used vivo. The core targets for identified using network pharmacology analysis, TCGA database analysis real-time PCR. Molecular docking performed determine binding energy. Protein tyrosine phosphatase non-receptor type 11 (PTPN11)-overexpressing cells constructed, then, viability expression levels proliferation- apoptosis-related proteins detected after treatment PTPN11 HNSCC. After treated MF, number colonies decreased, arrested increased. results showed that could inhibit proliferation via promoting shown be target molecular revealed exhibited strongest ability bind MF. Finally, attenuate effects increased decreased caused by overexpression, suggesting can progression regulating PTPN11. targeted PTPN11, arrest apoptosis, consequently exerting effective anti-tumor activity.